The rationale for treating allergic asthma with anti-IgE
An estimated two-thirds of asthma is allergic and >50% of severe asthma has an allergic component. An increased immunoglobulin (Ig)E production in response to environmental allergens (atopy) is the strongest detectable predisposing factor for the development of asthma, particularly when sensitisa...
Main Author: | E. Hamelmann |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2007-09-01
|
Series: | European Respiratory Review |
Subjects: | |
Online Access: | http://err.ersjournals.com/cgi/content/full/16/104/61 |
Similar Items
-
How to evaluate a patient's response to anti-IgE
by: S. T. Holgate
Published: (2007-09-01) -
Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases
by: J. Bousquet, et al.
Published: (2008-04-01) -
Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma
by: AlShareef S, et al.
Published: (2022-02-01) -
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
by: R. Buhl
Published: (2007-09-01) -
Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
by: Tajiri T, et al.
Published: (2023-01-01)